skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page

<< Back


Single Dose of Childbirth HIV Drug ‘Can Be Fatal’

HIV-positive women given a single dose of nevirapine during labor to prevent mother-to-baby transmission face an increased risk of resistance to the drug and premature death if later treated with a regimen containing nevirapine, researchers said recently. About 100,000 women annually receive nevirapine during childbirth in South Africa. The study, funded by the US National Institutes of Health, included 745 women in seven African countries and compared AIDS drug cocktails between two groups of women: those who received nevirapine during labor and those who did not. A routine interim safety review on Oct. 6 found that women who received nevirapine fared better on a nevirapine-sparing cocktail (lopinavir-boosted ritonavir, emtricitabine, and tenofovir). Of the 13 women with nevirapine-resistant HIV strains who received a cocktail including nevirapine (nevirapine, emtricitabine, and tenofovir), five (38 percent) either died or failed to control their virus. All 12 women with nevirapine-resistant HIV who took the nevirapine-sparing regimen were alive and had suppressed the virus. The independent safety review board recommended stopping this part of the trial, and researchers have begun notifying participants of the findings. Another part of the study, comparing the efficacy of nevirapine and lopinavir-boosted ritonavir in women not exposed to nevirapine, continues. Nevirapine resistance can be avoided by giving women a cheap, seven-day course of Combivir after their babies are delivered, researchers said. “I’m not saying nevirapine should not have been given to these women - it was the best we had at the time,” said the study’s Dr. Francesca Conradie of the University of Witwatersrand. “What we can do now is protect nevirapine (to ensure it can be safely used in their subsequent treatment).” Women who were given single-dose nevirapine should be closely monitored for resistance and switched to Kaletra if their virus shows evidence of resistance, the study group said. “The longer you leave them on a failing regimen, the greater the risk that they will become resistant to all the drugs they are taking,” Conradie said.
Date of Publication
Tamar Kahn
Article Type
General media
Article Category
International News
Antiretroviral Drugs
Drug Resistance
Mothers with HIV/AIDS
Perinatal Transmission
Studies or Surveys

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN. News Record #52051

<< Back

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources
STD Awareness Microsite
AIDS Gov Logo and Link CDC Logo and Link